PGNY · Progyny, Inc.
$25.53
-0.18 (-0.70%)
At close · Aug 19
Market Cap
$1.97B
Shares
76.73M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$25.53
Open$25.60
Day$25.41–25.90
52W close$16.30–32.36
Avg vol 30d1.1M
Short int4.5M · 5.8% float · 4.6d
Short vol31%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
−12%
below
RSI (14)
31
neutral
MACD trend
Negative
52-week position
57%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−19%
trailing
6-month return
+15%
trailing
YTD return
−1%
this year
Relative strength
+3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $29 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +67 funds added
Insider flow
Distributing
Net -$372.9K over 90 days · 100% sells
Short interest
Falling
5.85% of float · ▼ -3.1% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
310 holders — mid 3-yr range
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
Gross margin
24%
expanding
EPS growth
+14%
Y/Y
Free cash flow
$191.8M
Valuation
P/E 27.9
rich
Buyback
$142.5M
remaining
Balance sheet
$112.0M
net cash
Quant / Vol
risk profile
Volatility
55%
annualized · 1-yr
Max drawdown
−43%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Full Year 2026
Net income per diluted share
Initiated
$1.26 – $1.32
prior FY $0.65
midpoint +98.5% Y/Y
Adjusted earnings per diluted share
Initiated
$2.04 – $2.10
Third Quarter of 2026
Adjusted earnings per diluted share
Initiated
$0.50 – $0.52
Net income per diluted share
Initiated
$0.30 – $0.33
prior qtr $0.34
midpoint −7.4% QoQ
Prior guidance
period ended
· from the 8-K filed Feb 26, 2026
Adjusted earnings per diluted share
· First Quarter of 2026
$0.42 – $0.45
Revenue
· First Quarter of 2026
$319M – $332M
Adjusted EBITDA
· First Quarter of 2026
$51M – $55M
Net income per diluted share
· First Quarter of 2026
$0.24 – $0.27
Guided vs delivered
· last 8 settled
Per diluted share
Fourth Quarter of 2025
guided $0.14 – $0.17
$0.14
In line
Revenue
Three Month Period Ending December 31, 2025
guided $292.7M – $307.7M
$1.29B
Beat +329.3%
Per diluted share
Full Year 2025
guided $0.58 – $0.65
$0.65
In line
Per diluted share
Third Quarter of 2025
guided $0.10 – $0.14
$0.15
Beat +25.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
−12%
Bearish
RSI (14)
31
Neutral
MACD trend
Negative
Bearish
52-week position
57%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $29 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +67 funds added
Insider flow
Distributing
Net -$372.9K over 90 days · 100% sells
Short interest
Falling
5.85% of float · ▼ -3.1% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
310 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $16
Now $26 · 57%
Range high $32
vs 200-day avg +7%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adj. EBITDA non-GAAP | $62.1M | 2Q 2026 | — |
|
|
|||
| Adjusted Earnings Per Diluted Share non-GAAP | $1.04 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted EBITDA Margin non-GAAP | 17.7% | Q2 2026 | — |
|
|
|||
| ART Cycles per Unique Female Utilizer | 0.51 | 2Q 2026 | — |
| Assisted Reproductive Treatment (ART) Cycles | 32,645 | Six Months Ended June 30, 2026 | — |
| Average Members | 7,176,000 | Six Months Ended June 30, 2026 | — |
| Clients | 6,743 | 2Q 2026 | — |
| Female Utilization Rate | 0.49% | 2Q 2026 | — |
| Fertility and family building clients | 604 | Q2 2026 | — |
| Utilization - All Members | 0.85% | Six Months Ended June 30, 2026 | — |
| Utilization - Female Only | 0.71% | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PGNY
this stock
Progyny, Inc.
|
$1.97B | -0.6% | +10.4% | 27.9 | 5.8% |
|
UNH
Unitedhealth Group Inc
|
$353.59B | +17.7% | +11.8% | — | 1.7% |
|
CVS
CVS HEALTH Corp
|
$119.95B | +18.0% | +7.8% | 24.8 | 1.5% |
|
ELV
Elevance Health, Inc.
|
$87.01B | +13.7% | +12.5% | 17.8 | 2.6% |
|
CI
Cigna Group
|
$74.37B | +0.8% | +11.2% | 11.7 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PGNY | +0.4% | -18.6% | +14.7% | -18.0% | -0.6% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +0.9% | -21.5% | +3.2% | -20.9% | -13.4% |
Capital returns
Buyback program
· as of Aug 6, 2026
Authorized
$200.00M
Spent (derived)
$57.50M
Remaining
$142.50M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1551306
CUSIP
74340E103
13F (30d)
286 filings
281 filers
Visit website
Investor relations